Erratum: Acotiamide: First global approval (Drugs (2013) 73 (1377-1383) DOI: 10.1007/s40265-013-0100-9));Acotiamide: First global approval

Drugs

Volumn 73, Issue 12, 2013, Pages 1377-1383

  Nolan, Mary L ^a   Scott, Lesley J ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACOFIDE; ACOTIAMIDE; CISAPRIDE; PLACEBO; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ARTICLE; CHOLINESTERASE INHIBITION; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DYSPEPSIA; EUROPE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL MOTILITY; HUMAN; JAPAN; MAXIMUM PLASMA CONCENTRATION; NEPEAN DYSPEPSIA INDEX; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROLACTIN BLOOD LEVEL; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; STOMACH DISTENSION; STOMACH EMPTYING; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 84883216202     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0236-2     Document Type: Erratum

References (38)

1. Tack J, Talley NJ. Functional dyspepsia - symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol. 2013;10(3):134-41.
2. Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10(3):187-94.
3. Karamanolis GP, Tack J. Current management of functional dyspepsia: impact of Rome III subdivision. Ann Gastroenterol. 2012;25(2):96-9.
4. Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36(1):3-15.
5. Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol Motil. 2010;22(6):595-9.
6. Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791-800.
7. Astellas P. Conclusion of co-development and co-marketing agreement on a functional dyspepsia agent Z-338/YM443 in Japan with Zeria. 2008. http://www.astellas.com. Accessed 20 Jun 2013.
8. ®. 2013. http://www.astellas.com. Accessed 20 Jun 2013.
9. ® in Japan for treating functional dyspepsia. 2013. http://www.astellas.com. Accessed 20 Jun 2013.
10. Zeria Pharmaceutical Co. Ltd. Responding to cutting-edge medical demands. 2013. http://www.zeria.co.jp/english/comp/co-0501.html. Accessed 24 Jun 2013.
11. ® tablets 100 mg: Japanese prescribing information. 2013. http://www.zeria.co.jp/medi/data/acofide01/pdf/tenpu-201306.pdf. Accessed 18 Jun 2013.
12. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618-25, e173.
13. Tack JF, Stanghellini V, Holtmann G, et al. Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia [abstract no. Tu1359]. Gastroenterology. 2011;140(5 Suppl.1):S805.
14. Zeria Pharmaceutical Co. Ltd. To evaluate the efficacy and safety of acotiamide in subjects with functional dyspepsia [ClinicalTrials.gov identifier NCT00323817]. US National Institues of Health, ClinicalTrials.gov. 2011. http://www.clinicaltrials.gov. Accessed 14 Jun 2013.
15. Astellas Pharma Inc. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study of YM443 [Z 338, acotiamide] in subjects with functional dyspepsia [ClinicalTrials.gov identifier NCT00102310]. US National Institutes of Health, ClinicalTrials.gov. 2008. http://www.clinicaltrials.gov. Accessed 12 Jun 2013.
16. Talley NJ, et al. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial [abstract no. 1053]. Gastroenterology. 2008;134(4 Suppl.1):A157-8.
17. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821-8.
18. Matsueda K, Hongo M, Ushijima S, et al. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261-8.
19. Zeria Pharmaceutical Co. Ltd, Yamanouchi Pharmaceutical Co. Ltd. Zeria and Yamanouchi sign letter of intent for development and marketing of the gastroprokinetic Z-338. 2002. http://www.yamanouchi.com. Accessed 20 Jun 2013.
20. ® in Japan for treating functional dyspepsia. 2013. http://www.astellas.com/en/corporate/news/detail/launch-of-acofide-in-japan-for. html. Accessed 5 Jul 2013.
21. Yoshii K, Hirayama M, Nakamura T, et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. J Pharm Sci. 2011;100(11):4965-73.
22. Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1-3):31-5.
23. Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil. 2012;24(6):566-74, e256.
24. Kanemoto Y, Ishibashi H, Doi A, et al. An electrophysiological study of muscarinic and nicotinic receptors of rat paratracheal ganglion neurons and their inhibition by Z-338. Br J Pharmacol. 2002;135(6):1403-14.
25. Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res. 2000;36(2):69-81.
26. Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol. 2011;666(1-3):218-25.
27. Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther. 2000;294(1):33-7.
28. Morita H, Abe K, Ito Y, et al. Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach. Jpn J Pharmacol. 2002;89(4):356-65.
29. Akaike H, Jang II-S, Hori N, et al. Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema. J Smooth Muscle Res. 2010;46(1):31-47.
30. Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20(9):1051-9.
31. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009;21(3):272-80.
32. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540-5, e250-1.
33. Adam B, Liebregis T, Zschau NB, et al. Z-338 improves meal-induced symptoms in functional dyspepsia; a double-blind, randomized, placebo controlled crossover study [abstract no. T1266]. Gastroenterol. 2009;136(5 Suppl.1):A535.
34. Zeria Pharmaceutical Co. Ltd. The effects of Z-338 in subjects with and without functional dyspepsia [ClinicalTrials.gov identifier NCT00298194]. US National Institues of Health, ClinicalTrials.gov. 2009. http://www. clinicaltrials.gov. Accessed 25 Jun 2013.
35. Astellas Pharma Inc. A phase I, randomized, double-blind, placebo- and active-controlled, crossover study to evaluate the effect of repeat oral doses of YM443 on cardiac repolarization in healthy male and female adult subjects [ClinicalTrials.gov identifier NCT00850746] US National Institutes of Health, ClinicalTrials.gov. 2010. http://www.clinicaltrials.gov. Accessed 18 Jun 2013.
36. Oliver SD, Ward C, Ward J, et al. Z-338: phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects [abstract no. 948 plus poster]. In: 7th world conference on clinical pharmacology and therapeutics (CPT) and the 4th congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), 16-20 July 2000, Florence.
37. Furuta S, Kamada E, Omata T, et al. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol. 2004;497(2):223-31.
38. Matsueda K, Hongo M, Tack JF, et al. Efficacy of acotiamide (Z-338) in patients with postprandial distress syndrome or overlap of epigastric pain syndrome and postprandial distress syndrome in functional dyspepsia [abstract no. Tu1357]. Gastroenterology. 2011;140(5 Suppl. 1):S805.